3CLARK C E,GUTTMAN M.Dopamine agonist monotherapy in Parkinson's disease[J].Lancet,2002,360(9347):1767-1770. 被引量：1
4WOOTEN G F.Agonists vs levodopa in PD:the thrilla of whitha[J].Neurology,2003,60(3):360-362. 被引量：1
5OLANOW C W,WATTS R L,KOLLER W C.An algorithm(decision tree) for the management of Parkinson's disease (2001):treatment guidelines[J].Neurology,2001,56(Suppl 5):1-88. 被引量：1
6Parkinson Study Group.Pramipexole vs levodopa as initial treatmeat for Parkinson's disease:a randonized controlled trial[J].JAMA,2000,284(15):1931-1938. 被引量：1
3[2]CLARKE CE,GUTTMAN M.Dopamine agonist monotherapy in Parkinson's disease[J].Lancet,2002,360(9347):1767-1769. 被引量：1
4[4]PERACHON S,SCHWARTZ JC,SOKOLOFF P.Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1,D2 and D3 receptors[J].Eur J Pharmacol,1999,366(2-3):293-300. 被引量：1
5[5]KONDO T.Initial therapy for Parkinson's disease:levodopa vs dopamine receptor agonists[J].J Neurol,2002,249 Suppl 2:Ⅱ25-Ⅱ29. 被引量：1
7[7]ZOU L,JANKOVIC J,ROWE D,et al.Neuroprotection by pramipexole against dopamine- and levodopa- induced cytotoxicity[J].Life Sci,1999,64:1275-1285. 被引量：1
8[8]LING ZD,ROBIE HC,TONG CW,et al.Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures[J].J Pharmacol Exp Ther,1999,289(1):202-210. 被引量：1
9[9]TAKASHIMA H,TSUJIHATA M,KISHIKAWA M,et al.Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D2 receptors[J].Exp Neurol,1999,159(1):98-104. 被引量：1
10[10]FERRARIO JE,DELFINO MA,STEFANO AV,et al.Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process[J].Neurosci Res,2003,47(4):431-436. 被引量：1
